Synthesis of bulk, dense, nanocrystalline yttrium aluminum garnet from amorphous powders

Amorphous powders of Al2O3x2014;37.5 mol% Y2O3 (yttrium aluminum garnet (YAG)) were prepared by coprecipitation, decomposed at 800xB0;C, and hot-pressed uniaxally at low temperature (600xB0;C) and a moderate pressure (750 MPa). Optimum conditions yielded microstructures with only 2% porosity and partial crystallization of YAG. Further processing using high quasi-hydrostatic pressure (1 GPa) at 1000xB0;C enabled the production of fully crystallized YAG with gt;96% relative density and a nanocrystalline grain size of x223C;70 nm. 13

Liver Allograft: Its Use in Chronic Active Hepatitis with Macronodular Cirrhosis, Hepatitis B Surface Antigen

A patient suffering from chronic active hepatitis with macronodular cirrhosis, positive for hepatitis B surface antigen (HBsAg), was treated with an orthotopic liver allograft. The HBs antigenemia, as measured with several precipitation tests and by complement fixation, became negative after transplantation and remained so for about 2½ months. During the interval, very low titers of the antigen were detectable by radioimmunoassay. At about three months after transplantation, she had an attack of acute hepatitis, at which time HBsAg became detectable by all tests. She recovered, but progressive liver disease developed during the remaining 1½ years of her life. She died of disseminated nocardiosis and candidiasis with deteriorating hepatic function. The homograft at autopsy showed no evidence of rejection, but was the site of chronic active liver disease, although of a different pathologic pattern than that affecting her native liver. The differences in histology may reflect the influence of chronic immunosuppression on the features of chronic active hepatitis. © 1979, American Medical Association. All rights reserved

The quantized Hall conductance of a single atomic wire: A proposal based on synthetic dimensions

We propose a method by which the quantization of the Hall conductance can be directly measured in the transport of a one-dimensional atomic gas. Our approach builds on two main ingredients: (1) a constriction optical potential, which generates a mesoscopic channel connected to two reservoirs, and (2) a time-periodic modulation of the channel, specifically designed to generate motion along an additional synthetic dimension. This fictitious dimension is spanned by the harmonic-oscillator modes associated with the tightly-confined channel, and hence, the corresponding "lattice sites" are intimately related to the energy of the system. We analyze the quantum transport properties of this hybrid two-dimensional system, highlighting the appealing features offered by the synthetic dimension. In particular, we demonstrate how the energetic nature of the synthetic dimension, combined with the quasi-energy spectrum of the periodically-driven channel, allows for the direct and unambiguous observation of the quantized Hall effect in a two-reservoir geometry. Our work illustrates how topological properties of matter can be accessed in a minimal one-dimensional setup, with direct and practical experimental consequences.

The energy partitioning of non-thermal particles in a plasma: or the Coulomb logarithm revisited

The charged particle stopping power in a highly ionized and weakly to moderately coupled plasma has been calculated to leading and next-to-leading order by Brown, Preston, and Singleton (BPS). After reviewing the main ideas behind this calculation, we use a Fokker-Planck equation derived by BPS to compute the electron-ion energy partitioning of a charged particle traversing a plasma. The motivation for this application is ignition for inertial confinement fusion -- more energy delivered to the ions means a better chance of ignition, and conversely. It is therefore important to calculate the fractional energy loss to electrons and ions as accurately as possible, as this could have implications for the Laser Megajoule (LMJ) facility in France and the National Ignition Facility (NIF) in the United States. The traditional method by which one calculates the electron-ion energy splitting of a charged particle traversing a plasma involves integrating the stopping power dE/dx. However, as the charged particle slows down and becomes thermalized into the background plasma, this method of calculating the electron-ion energy splitting breaks down. As a result, the method suffers a systematic error of order T/E0, where T is the plasma temperature and E0 is the initial energy of the charged particle. In the case of DT fusion, for example, this can lead to uncertainties as high as 10% or so. The formalism presented here is designed to account for the thermalization process, and in contrast, it provides results that are near-exact.Comment: 10 pages, 3 figures, invited talk at the 35th European Physical Society meeting on plasma physic

Middle East respiratory syndrome

The Middle East respiratory syndrome is caused by a coronavirus that was first identified in Saudi Arabia in 2012. Periodic outbreaks continue to occur in the Middle East and elsewhere. This report provides the latest information on MERS

Polycrystalline Yttrium Aluminum Garnet Fibers from Colloidal Sols

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66320/1/j.1151-2916.1995.tb08626.x.pd

Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic

Background: Antigen testing has become an essential part of fighting the ongoing COVID-19 pandemic. With the continual increase in available tests, independent and extensive comparative evaluations using data from external quality assessment (EQA) studies to evaluate test performance between different users are required.Objectives: An EQA scheme was established to assess the sensitivity of antigen tests and the potential impact of circulating SARS-CoV-2 strains on their performance.Study design: Panels were prepared for three challenges in 2021 containing inactivated SARS-CoV-2-positive samples of various genetic strains (including variants of concern, VOCs) at different concentrations, and negative samples. Data was analysed based on qualitative testing results in relation to the antigen test used. Results: Participants registered for each individual challenge in any combination. In total, 258 respondents from 27 countries worldwide were counted submitting 472 datasets. All core samples were correctly reported by 76.7 to 83.1% at participant level and by 73.5 to 83.8% at dataset level. Sensitivity differences could be shown in viral loads and SARS-CoV-2 strains/variants including the impact on performance by a B.1.1.7-like mutant strain with a deletion in the nucleoprotein gene. Lateral flow rapid antigen tests showed a higher rate of false negatives in general compared with automated point-of-care tests and laboratory ELISA/immunoassays.Conclusions: EQA schemes can provide valuable data to inform participants about weaknesses in their testing process or methods and support ongoing assay evaluations for regulatory approval or post-market surveillance

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. A booster vaccination with MVA-MERS-S is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n=1) and the S2 subunit (n=3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials